Syphilis Treatment Drugs Market Share

North America Market Statistics

On the basis of geographical analysis, the syphilis treatment drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America industry is predicted to dominate majority revenue share by 2036, on the back of high awareness about the disease, favorable public health insurance plans and growing advancements in the healthcare sector.

Europe Market Analysis

Europe is also assessed to acquire a large share in the syphilis treatment drugs market during the forecast period owing to the rising R&D activities to develop effective treatment for STDs in the region. However, the market in the Middle East & Africa is projected to witness noteworthy growth over the forecast period, which can be ascribed to increasing occurrence of syphilis in Africa, emergence of new point-of-care (POC) testing concepts and increasing number of public health labs to provide STD testing. According to the World Health Organization (WHO), Africa accounted for the highest prevalence of syphilis in the world.

Frequently Asked Questions (FAQ)

Increasing incidences of unprotected sex worldwide and growing occurrence of syphilis in developing nations are major growth drivers for the market.

The market is anticipated to attain a notable CAGR over the forecast period, i.e., 2021 â€“ 2029.

Lack of trained laboratory personnel in under developed nations is estimated to hamper the market growth.

Middle East & Africa region will provide more business growth opportunities on the back of high prevalence of syphilis in Africa.

The major players in the market are GlaxoSmithKline plc, Johnson & Johnson Services, Inc., F. Hoffman-La Roche Ltd, Abbott Laboratories, PerkinElmer, Inc., and others.

Syphilis Treatment Drugs Market Share